PT-141 Research

Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY

The foundational review establishing PT-141’s mechanism and clinical rationale. PT-141 was developed as a next-generation analog of Melanotan II with higher selectivity for MC4R — the melanocortin receptor subtype most involved in sexual behavior — and a better safety profile. The paper documents PT-141’s central nervous system mechanism: unlike PDE5 inhibitors (Viagra, Cialis) which increase blood flow to the genitals, PT-141 acts in the hypothalamus to modulate the neural pathways governing desire and arousal itself. This distinction is clinically important — it means PT-141 can work in patients where vascular mechanisms are intact but desire is absent, or where PDE5 inhibitors have failed. This paper set the stage for the full clinical development program that led to FDA approval.

Kingsberg SA, Clayton AH, Portman D, et al.

The pivotal Phase 3 trials that led to FDA approval of bremelanotide (Vyleesi) in 2019 — making PT-141 only the second drug ever approved for female sexual desire disorder, and the first with a non-hormonal, CNS mechanism. Two identical randomized, double-blind, placebo-controlled trials (RECONNECT 301 and 302) enrolled premenopausal women with HSDD. Bremelanotide 1.75mg subcutaneous significantly improved both the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale compared to placebo at 24 weeks. Nausea was the most common adverse event (40% bremelanotide vs 1.3% placebo), but was generally mild and transient. The safety profile was otherwise favorable with small, transient blood pressure increases that resolved within 8–10 hours.

Kingsberg SA, et al. — RECONNECT Study Group

The 52-week open-label extension of the RECONNECT trials, examining bremelanotide’s long-term safety and sustained efficacy. No new safety signals emerged over 52 weeks of continued use, and improvements in HSDD symptoms were maintained throughout the extension period. This long-term data was critical for the FDA approval package — demonstrating that the benefits observed in the 24-week trials are sustained with continued treatment and that no unexpected safety concerns emerge over time. For women using bremelanotide on an as-needed basis (up to 8 doses per month), the compound maintained its efficacy without tolerance development or new adverse effects.

PMC Research Group

A comprehensive review covering bremelanotide’s full development history, mechanism of action, and clinical evidence across both female and male sexual dysfunction. The paper documents the earliest clinical study in women with HSDD (2006), the Phase 2b dose-finding trials that identified 1.75mg as the optimal dose, and the RECONNECT Phase 3 results. It also covers PT-141’s off-label use in men — including studies showing efficacy in sildenafil non-responders and a synergistic effect when combined with PDE5 inhibitors. The review explains the different mechanisms in men vs women: in men, MC3R/MC4R stimulation causes nitric oxide release and direct vasodilation in penile tissue; in women, the pathway is neurochemical — modulating the neurotransmitter imbalance that underlies reduced desire in HSDD.

World Journal of Men’s Health Research Group

A review of PT-141’s evidence for male erectile dysfunction — the off-label application that drives most research peptide use of this compound. The paper documents Phase 1 and 2 clinical data: at 20mg intranasal dosing, PT-141 produced significantly greater duration of base rigidity ≥80% vs placebo. In men with ED who were non-responsive to sildenafil, 34% of the PT-141 group reported significantly better results vs 9% placebo — a clinically meaningful response rate in a notoriously treatment-resistant population. A combination study showed PT-141 plus sildenafil produced a significantly greater erectile response than sildenafil alone. The paper also covers the pivot from intranasal to subcutaneous delivery after blood pressure concerns with the nasal route, and notes ongoing Phase 2 trials investigating a co-formulation of bremelanotide plus a PDE5 inhibitor for male ED.